{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:08:08Z","timestamp":1787987288710,"version":"build-2784847793"},"reference-count":452,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Development and Technology"],"published-print":{"date-parts":[[2025,9,14]]},"DOI":"10.1080\/10837450.2025.2562196","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:40:08Z","timestamp":1758278408000},"page":"1147-1182","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Current and emerging therapies for dry and neovascular age-related macular degeneration"],"prefix":"10.1080","volume":"30","author":[{"given":"Ghayth M.","family":"Abdulrazzaq","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul","place":["Mosul, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan M.","family":"Merkhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Mosul","place":["Mosul, Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashiru","family":"Billa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-7499","authenticated-orcid":false,"given":"Raid G.","family":"Alany","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kingston University London","place":["Kingston upon Thames, UK"]},{"name":"School of Pharmacy, The University of Auckland","place":["Auckland, New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried MK.","family":"Amoaku","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust","place":["Nottingham, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naing L.","family":"Tint","sequence":"additional","affiliation":[{"name":"Princess Alexandra Eye Pavilion","place":["Edinburgh, UK"]},{"name":"University of Edinburgh","place":["Edinburgh, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Leicester Institute for Pharmaceutical Innovation (LIPI), Leicester School of Pharmacy, De Montfort University","place":["Leicester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Qutachi","sequence":"additional","affiliation":[{"name":"Leicester Institute for Pharmaceutical Innovation (LIPI), Leicester School of Pharmacy, De Montfort University","place":["Leicester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"AAO. 2021. The intravitreal sunitinib malate depot GB-102 appears promising against wet AMD. Eye Care. https:\/\/www.practiceupdate.com\/content\/aao-2021-the-intravitreal-sunitinib-malate-depot-gb-102-appears-promising-against-wet-amd\/127729"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18572"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(99)00072-7"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051330"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.04.009"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000851"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.411"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00184273"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.06.018"},{"key":"e_1_3_4_11_1","unstructured":"Apellis Pharmaceuticals I. 2018. Apellis Pharmaceuticals I. Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration. Identifier: NCT03525600."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-009-0272-3"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61820-1"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.4.529"},{"issue":"3","key":"e_1_3_4_15_1","first-page":"26","article-title":"Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration","volume":"123","author":"Avetisov SE","year":"2007","unstructured":"Avetisov SE, Kiseleva TN, Lagutina I, Kravchuk EA. 2007. Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration. Vestn Oftalmol. 123(3):26\u201328.","journal-title":"Vestn Oftalmol"},{"key":"e_1_3_4_16_1","first-page":"34","article-title":"Sustained-release sunitinib malate for neovascular AMD","volume":"17","author":"Aziz AA","year":"2020","unstructured":"Aziz AA, Khan M, Shafi N, Khanani AM. 2020. Sustained-release sunitinib malate for neovascular AMD. Retin Physician. 17:34, 34, 43.","journal-title":"Retin Physician"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-4143-1"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0566-9"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01373-3"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0118"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.02.002"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1346079"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-014-8308-8"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.03.068"},{"key":"e_1_3_4_25_1","unstructured":"Bright Focus Foundations. [date unknown]. Age-related macular degeneration: facts & figures. Macular degeneration Research. https:\/\/www.brightfocus.org\/macular\/article\/age-related-macular-facts-figures#"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2021.10.013"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2019.08.001"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.117"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2003.00076.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835f8e55"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.04.020"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2010.09.019"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3RI0615-239R"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2017.05.011"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/gels7020058"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/454295"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.10.047"},{"key":"e_1_3_4_39_1","unstructured":"ClinicalTrials.gov. [date unknown]. A phase 3 multicenter randomized double-masked controlled study of squalamine lactate (MSI-1256F) for injection for the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration. EUCTR. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-001235-30-ES"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31822058a3"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/360764"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.02.018"},{"issue":"11","key":"e_1_3_4_43_1","first-page":"633","article-title":"[Surgery of macular neovascular subretinal membranes]","volume":"16","author":"Coscas G","year":"1993","unstructured":"Coscas G, Meunier I. 1993. [Surgery of macular neovascular subretinal membranes]. J Fr Ophtalmol. 16(11):633\u2013641.","journal-title":"J Fr Ophtalmol"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2011.577130"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01218.x"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14204273"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112792"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2005.04.012"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31827e25e0"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2009.08.001"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.3.329"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.4.645"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2007.07.001"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4114"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.03.003"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S73705"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.017"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0029(19970115)36:2<130::AID-JEMT6>3.0.CO;2-T"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00850-3"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000058747"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0662"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-19910201-12"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.01014.x"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.11.035"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303604110"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10050"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.7.39"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00239-9"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000606"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/802059"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.09.010"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32835f8eaa"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165089"},{"issue":"7","key":"e_1_3_4_74_1","first-page":"1503","article-title":"Human fetal retinal pigment epithelial cells induce apoptosis in the T-cell line Jurkat","volume":"40","author":"Farrokh-Siar L","year":"1999","unstructured":"Farrokh-Siar L, et\u00a0al. 1999a. Human fetal retinal pigment epithelial cells induce apoptosis in the T-cell line Jurkat. Invest Ophthalmol Vis Sci. 40(7):1503\u20131511.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.19.2.89.5331"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M107876200"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032488"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200504213521619"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2002.800115.x"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1159\/000268032"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-090413-025610"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050225"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23157"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/690243"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02496-x"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.4137\/OED.S4878"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890600946724"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005022.pub3"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885328209104289"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2016.02.010"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-4636(199701)34:1<87::aid-jbm12>3.0.co;2-m"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-1724"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2009.02108.x"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5b00129"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2015.11.051"},{"issue":"4","key":"e_1_3_4_97_1","first-page":"431","article-title":"Transplantation of cultured human retinal cells to monkey retina","volume":"56","author":"Gouras P","year":"1984","unstructured":"Gouras P, Flood MT, Kjeldbye H. 1984. Transplantation of cultured human retinal cells to monkey retina. An Acad Bras Cienc. 56(4):431\u2013443.","journal-title":"An Acad Bras Cienc"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2005.02.002"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.012"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2020.02.006"},{"key":"e_1_3_4_101_1","first-page":"123","article-title":"Retinal pigment epithelium resurfacing of aged submacular human Bruch\u2019s membrane","volume":"102","author":"Gullapalli VK","year":"2004","unstructured":"Gullapalli VK, et\u00a0al. 2004. Retinal pigment epithelium resurfacing of aged submacular human Bruch\u2019s membrane. Trans Am Ophthalmol Soc. 102:123\u2013138.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.09.006"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1089\/ten.1999.5.187"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-4370-8_9"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.12.041"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/term.2089"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050390"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12675"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-014-1431-z"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30979-0"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.11.011"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264221126061"},{"key":"e_1_3_4_114_1","unstructured":"Hemera Biosciences. [date unknown]. Hemera biosciences\u2019s competitors and alternates. https:\/\/tracxn.com\/d\/companies\/hemera-biosciences\/__-ChXj3kSQaJrOyeuPR1hSmC0dTxn0-c-9U_Momt9f2c#competitors-and-alternates"},{"key":"e_1_3_4_115_1","unstructured":"Hepp R. 2023. Tackling geographic atrophy with gene therapy. Rertina Today. https:\/\/retinatoday.com\/articles\/2023-may-june\/tackling-geographic-atrophy-with-gene-therapy"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702823"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2021.1880863"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338749"},{"key":"e_1_3_4_119_1","unstructured":"Hutton D. 2024. Adverum biotechnologies releases positive preliminary efficacy safety data from LUNA phase 2 trial of Ixo-vec in patients with wet AMD. Ophthalmology Times. https:\/\/www.ophthalmologytimes.com\/view\/adverum-biotechnologies-releases-positive-preliminary-efficacy-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-009-1263-7"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101260"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100010064022"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2013.01.019"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713689808951220"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-5155(99)00208-7"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.0861"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.001"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98568-7"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.08.024"},{"issue":"7","key":"e_1_3_4_130_1","first-page":"4305","article-title":"Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD","volume":"61","author":"Jaffe GJ","year":"2020","unstructured":"Jaffe GJ, et\u00a0al. 2020. Development of IONIS-FB-LRx to treat geographic atrophy associated with AMD. Invest Ophthalmol Visual Sci. 61(7):4305.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40778-015-0014-4"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.002"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702761"},{"issue":"12","key":"e_1_3_4_134_1","first-page":"1026","article-title":"Age related macular degeneration: should your patients be taking additional supplements?","volume":"36","author":"Jones AA.","year":"2007","unstructured":"Jones AA. 2007. Age related macular degeneration: should your patients be taking additional supplements? Aust Fam Physician. 36(12):1026\u20131028.","journal-title":"Aust Fam Physician"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010859.pub2"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1382853"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.01.090"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.016"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13794"},{"issue":"11","key":"e_1_3_4_140_1","first-page":"754","article-title":"[Preclinical study of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets transplantation]","volume":"120","author":"Kamao H.","year":"2016","unstructured":"Kamao H. 2016. [Preclinical study of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets transplantation]. Nippon Ganka Gakkai Zasshi. 120(11):754\u2013763.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2019.08.015"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2007.10"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4097"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.09.017"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000838"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S224456"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363220-00016"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.182162"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.01014.x"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100154"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181e2266d"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1101\/gr.219089.116"},{"issue":"8","key":"e_1_3_4_155_1","first-page":"447","article-title":"Toward a non-invasive solution of wet AMD: Sunitinib, Pazopanib, and Axitinib Eyedrops versus intraocular injection of aflibercept","volume":"62","author":"Kim K-H","year":"2021","unstructured":"Kim K-H, Oh JY, Cho D, Kim MJJ. 2021. Toward a non-invasive solution of wet AMD: Sunitinib, Pazopanib, and Axitinib Eyedrops versus intraocular injection of aflibercept. Invest Ophthalmol Visual Sci. 62(8):447.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02179.x"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20961"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1093110"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.10.040"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01146-6"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2003.11.069"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.81.2.154"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1532-17.2018"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.635"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.06.040"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2004.09.029"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3386-y"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357369"},{"issue":"8","key":"e_1_3_4_169_1","first-page":"1959","article-title":"Abicipar pegol in neovascular age-related macular degeneration (nAMD): comparability between Japanese and non-Japanese patients, and treatment effects on polypoidal choroidal vasculopathy (PCV) and non-PCV patients","volume":"58","author":"Kunimoto D","year":"2017","unstructured":"Kunimoto D, et\u00a0al. 2017. Abicipar pegol in neovascular age-related macular degeneration (nAMD): comparability between Japanese and non-Japanese patients, and treatment effects on polypoidal choroidal vasculopathy (PCV) and non-PCV patients. Invest Ophthalmol Visual Sci. 58(8):1959.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20190129-13"},{"issue":"9","key":"e_1_3_4_171_1","first-page":"5193","article-title":"Phase 3 evaluation of the efficacy and safety of abicipar compared with ranibizumab for treatment of neovascular age-related macular degeneration (nAMD)","volume":"60","author":"Kunimoto D.","year":"2019","unstructured":"Kunimoto D. 2019. Phase 3 evaluation of the efficacy and safety of abicipar compared with ranibizumab for treatment of neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Visual Sci. 60(9):5193.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002789"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(85)33819-8"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-013-4961-y"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100846"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008732.pub2"},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71576-4"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01994-9"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.12.1714"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2005.09.008"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.08.007"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29041"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)62603-5"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009495"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-7347.2012.05.001"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60282-7"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713689609017657"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020241"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000428"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-00656-y"},{"issue":"1","key":"e_1_3_4_192_1","first-page":"204","article-title":"Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina","volume":"37","author":"Little CW","year":"1996","unstructured":"Little CW, et\u00a0al. 1996. Transplantation of human fetal retinal pigment epithelium rescues photoreceptor cells from degeneration in the Royal College of Surgeons rat retina. Invest Ophthalmol Vis Sci. 37(1):204\u2013211.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-04007-5"},{"issue":"3","key":"e_1_3_4_194_1","first-page":"586","article-title":"Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS rat","volume":"30","author":"Lopez R","year":"1989","unstructured":"Lopez R, et\u00a0al. 1989. Transplanted retinal pigment epithelium modifies the retinal degeneration in the RCS rat. Invest Ophthalmol Vis Sci. 30(3):586\u2013588.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-012-9645-8"},{"key":"e_1_3_4_196_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2006.11.023"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(00)00179-4"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1163\/156856298X00721"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(01)00172-7"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3619-8"},{"key":"e_1_3_4_201_1","first-page":"35","article-title":"Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration","volume":"5","author":"Lutty G","year":"1999","unstructured":"Lutty G, Grunwald J, Majji AB, Uyama M, Yoneya S. 1999. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis. 5:35.","journal-title":"Mol Vis"},{"key":"e_1_3_4_202_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12482"},{"key":"e_1_3_4_203_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2672"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0607-4"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.029"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.06.049"},{"key":"e_1_3_4_207_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081785"},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608368"},{"key":"e_1_3_4_210_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.112"},{"key":"e_1_3_4_211_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-869-0_28"},{"key":"e_1_3_4_212_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-12833"},{"key":"e_1_3_4_213_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108071"},{"key":"e_1_3_4_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.04.037"},{"key":"e_1_3_4_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01055-2"},{"key":"e_1_3_4_216_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0923"},{"key":"e_1_3_4_217_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19252"},{"key":"e_1_3_4_218_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8125267"},{"key":"e_1_3_4_219_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622311415895"},{"key":"e_1_3_4_220_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14040827"},{"key":"e_1_3_4_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.08.042"},{"key":"e_1_3_4_222_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574888x16666210804112104"},{"key":"e_1_3_4_223_1","unstructured":"National Institute for Health Care and Excellence. 2013. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). https:\/\/bmec.swbh.nhs.uk\/wp-content\/uploads\/2013\/03\/NICE-guidelines-ILUVIEN-for-chronic-DMO-November-2013.pdf"},{"key":"e_1_3_4_224_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.06.004"},{"key":"e_1_3_4_225_1","unstructured":"NCT00056836. [date unknown]. A study to evaluate rhuFab V2 in subjects with minimally classic or occult subfoveal neovascular macular degeneration. ClinicalTrials.gov. https:\/\/ctv.veeva.com\/study\/a-study-to-evaluate-rhufab-v2-in-subjects-with-minimally-classic-or-occult-subfoveal-neovascular-mac"},{"key":"e_1_3_4_226_1","unstructured":"NCT00061594. [date unknown]. A study to compare rhuFab V2 with verteporfin photodynamic in treating subfoveal neovascular macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00061594"},{"key":"e_1_3_4_227_1","unstructured":"NCT00089830. [date unknown]. A safety and efficacy study of MSI-1256F (squalamine lactate) to treat \u2018wet\u2019 age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00089830"},{"key":"e_1_3_4_228_1","unstructured":"NCT00094120. [date unknown]. MSI-1256F (squalamine lactate) in combination with verteporfin in patients with \u2018wet\u2019 age-related macular degeneration (AMD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00094120"},{"key":"e_1_3_4_229_1","unstructured":"NCT00306488. [date unknown]. OT-551 antioxidant eye drops to treat geographic atrophy in age-related macular degeneration. ClinicalTrials.gov. https:\/\/www.cochranelibrary.com\/es\/central\/doi\/10.1002\/central\/CN-02018289\/full"},{"key":"e_1_3_4_230_1","unstructured":"NCT00333476. [date unknown]. A study of MSI-1256F (squalamine lactate) to treat \u2018wet\u2019 age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00333476"},{"key":"e_1_3_4_231_1","unstructured":"NCT00379795. [date unknown]. An extension study to evaluate the safety and tolerability of ranibizumab in subjects with choroidal neovascularization secondary to AMD or macular edema secondary to RVO. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00379795"},{"key":"e_1_3_4_232_1","unstructured":"NCT00395057. [date unknown]. A study using intravitreal injections of a small interfering RNA in patients with age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00395057"},{"key":"e_1_3_4_233_1","unstructured":"NCT00429936. [date unknown]. Study of fenretinide in the treatment of geographic atrophy associated with dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT00429936."},{"key":"e_1_3_4_234_1","unstructured":"NCT00447954. [date unknown]. A study of an encapsulated cell technology (ECT) implant for patients with atrophic macular degeneration. ClinicalTrials.gov. https:\/\/www.cochranelibrary.com\/web\/cochrane\/content?templateType=full&urlTitle=\/central\/doi\/10.1002\/central\/CN-01598193&doi=10.1002\/central\/CN-01598193&type=central&contentLanguage="},{"key":"e_1_3_4_235_1","unstructured":"NCT00463320. [date unknown]. A study to evaluate the safety tolerability and Pk of pazopanib eye drops in healthy adult and elderly subjects. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00463320"},{"key":"e_1_3_4_236_1","unstructured":"NCT00466076. [date unknown]. Copaxone in age related macular degeneration. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT00466076?V_1=View"},{"key":"e_1_3_4_237_1","unstructured":"NCT00485394. [date unknown]. The OMEGA study: use of eye drops to treat geographic atrophy associated with age-related macular degeneration (Dry AMD) (OMEGA). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00485394"},{"key":"e_1_3_4_238_1","unstructured":"NCT00509795. [date unknown]. Vascular endothelial growth factor VEGF trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW1). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00509795"},{"key":"e_1_3_4_239_1","unstructured":"NCT00541333. [date unknown]. Weekly vaccination with copaxone as a potential therapy for dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00541333"},{"key":"e_1_3_4_240_1","unstructured":"NCT00557791. [date unknown]. Safety & efficacy study evaluating the combination of bevasiranib & lucentis therapy in wet AMD (CARBON). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT00557791"},{"key":"e_1_3_4_241_1","unstructured":"NCT00637377. [date unknown]. Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00637377"},{"key":"e_1_3_4_242_1","unstructured":"NCT00804921. [date unknown]. Effectiveness of oral acetazolamide brimonidine tartarate and anterior chamber paracentesis in intraocular pressure (IOP) after bevacizumab. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00804921"},{"key":"e_1_3_4_243_1","unstructured":"NCT00864838. [date unknown]. Oral acetazolamide brimonidine tartarate and anterior chamber paracentesis for ocular hypertension control after intravitreal bevacizumab. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT00864838"},{"key":"e_1_3_4_244_1","unstructured":"NCT00877032. [date unknown]. Safety and tolerability study of RN6G in patients with dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00877032"},{"key":"e_1_3_4_245_1","unstructured":"NCT00935883. [date unknown]. Complement inhibition with eculizumab for the treatment of non-exudative macular degeneration (AMD) (COMPLETE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00935883"},{"key":"e_1_3_4_246_1","unstructured":"NCT00950638. [date unknown]. A study of ARC1905 (anti-C5 aptamer) in subjects with dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT00950638"},{"key":"e_1_3_4_247_1","unstructured":"NCT01003691. [date unknown]. Safety and tolerability study of RN6G in subjects with advanced dry age-related macular degeneration including geographic atrophy. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01003691"},{"key":"e_1_3_4_248_1","unstructured":"NCT01072214. [date unknown]. A safety study to evaluate pazopanib eye drops in healthy volunteers. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01072214"},{"key":"e_1_3_4_249_1","unstructured":"NCT01089517. [date unknown]. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus lucentis for neovascular age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01089517"},{"key":"e_1_3_4_250_1","unstructured":"NCT01154062. [date unknown]. A study to evaluate pazopanib tablets in patients who have neovascular age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01154062"},{"key":"e_1_3_4_251_1","unstructured":"NCT01157715. [date unknown]. A randomized double-masked multicenter controlled study of intravitreal KH902 in patients with neovascular AMD (AURORA). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01157715"},{"key":"e_1_3_4_252_1","unstructured":"NCT01170767. [date unknown]. French evaluation group avastin versus lucentis. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01170767"},{"key":"e_1_3_4_253_1","unstructured":"NCT01242254. [date unknown]. A study assessing the safety and efficacy of multiple intravitreal KH902 in patients with CNV due to AMD (HOPE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01242254"},{"key":"e_1_3_4_254_1","unstructured":"NCT01255462. [date unknown]. Intravitreal LFG316 in patients with advanced age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01255462"},{"key":"e_1_3_4_255_1","unstructured":"NCT01342926. [date unknown]. Clinical study to investigate safety and efficacy of GSK933776 in adult patients with geographic atrophy secondary to age-related macular degeneration. ClinicalTrials.gov. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01594529\/full"},{"key":"e_1_3_4_256_1","unstructured":"NCT01397409. [date unknown]. Evaluation of AGN-150998 in exudative age-related macular degeneration (AMD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01397409"},{"key":"e_1_3_4_257_1","unstructured":"NCT01436864. [date unknown]. A randomized double-masked multicenter sham-controlled safety and efficacy study of KH902 in patients with wet AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01436864"},{"key":"e_1_3_4_258_1","unstructured":"NCT01442064. [date unknown]. An extension study to evaluate safety and tolerability of ranibizumab in macular edema secondary to retinal vein occlusion (cohort 2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01442064"},{"key":"e_1_3_4_259_1","unstructured":"NCT01445548. [date unknown]. Sirolimus for advanced age-related macular degeneration (SIRGA2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01445548"},{"key":"e_1_3_4_260_1","unstructured":"NCT01494805. [date unknown]. Safety and efficacy study of rAAV.sFlt-1 in patients with exudative age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01494805"},{"key":"e_1_3_4_261_1","unstructured":"NCT01527500. [date unknown]. Intravitreal LFG316 in patients with age-related macular degeneration (AMD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01527500"},{"key":"e_1_3_4_262_1","unstructured":"NCT01577381. [date unknown]. Efficacy safety and tolerability study of RN6G in subjects with geographic atrophy secondary to age-related macular degeneration. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01577381"},{"key":"e_1_3_4_263_1","unstructured":"NCT01601483. [date unknown]. Efficacy and safety study of MC-1101 1% TID in the treatment of nonexudative age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01601483?term=NCT01013376%20NCT01601483%20NCT02127463&rank=2"},{"key":"e_1_3_4_264_1","unstructured":"NCT01601483. [date unknown]. Efficacy and safety study of MC-1101 1% TID in the treatment of nonexudative age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01601483"},{"key":"e_1_3_4_265_1","unstructured":"NCT01602120. [date unknown]. An extension study to evaluate the long-term safety of lampalizumab in participants with geographic atrophy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01602120"},{"key":"e_1_3_4_266_1","unstructured":"NCT01675947. [date unknown]. Intravitreal injections of sirolimus in the treatment of geographic atrophy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01675947"},{"key":"e_1_3_4_267_1","unstructured":"NCT01835015. [date unknown]. Pharmacokinetics of CLG561 in patients with advanced age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01835015"},{"key":"e_1_3_4_268_1","unstructured":"NCT01922128. [date unknown]. Safety study of a topical treatment for dry age related macular degeneration. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT01922128."},{"key":"e_1_3_4_269_1","unstructured":"NCT01941082. [date unknown]. A study of RO6867461 administered in single- and multiple-ascending doses in patients with wet age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01941082"},{"key":"e_1_3_4_270_1","unstructured":"NCT01944839. [date unknown]. A phase 3 safety and efficacy study of Fovista\u00ae (E10030) intravitreous administration in combination with Lucentis\u00ae compared to Lucentis\u00ae monotherapy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT01944839"},{"key":"e_1_3_4_271_1","unstructured":"NCT02022540. [date unknown]. Phase 1 study of topical ocular PAN-90806 for neovascular AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02022540"},{"key":"e_1_3_4_272_1","unstructured":"NCT02033668. [date unknown]. Pharmacokinetic (PK) study of GSK933776 in healthy volunteers. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01577381"},{"key":"e_1_3_4_273_1","unstructured":"NCT02076919. [date unknown]. First-in-human study of LHA510 in elderly subjects and patients with age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02076919"},{"key":"e_1_3_4_274_1","unstructured":"NCT02087085. [date unknown]. A safety and efficacy study of brimonidine intravitreal implant in geographic atrophy secondary to age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02087085"},{"key":"e_1_3_4_275_1","unstructured":"NCT02130531. [date unknown]. Pharmacokinetic and pharmacodynamic study of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02130531"},{"key":"e_1_3_4_276_1","unstructured":"NCT02181504. [date unknown]. A study of abicipar pegol in Japanese patients with neovascular age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02181504"},{"key":"e_1_3_4_277_1","unstructured":"NCT02222207. [date unknown]. Regorafenib eye drops: investigation of efficacy and safety in neovascular age related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02222207"},{"key":"e_1_3_4_278_1","unstructured":"NCT02230228. [date unknown]. Phase 1 safety study of ALK-001 in healthy volunteers. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02230228"},{"key":"e_1_3_4_279_1","unstructured":"NCT02288559. [date unknown]. A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to participants with geographic atrophy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02288559"},{"key":"e_1_3_4_280_1","unstructured":"NCT02348359. [date unknown]. X-82 to treat age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02348359"},{"key":"e_1_3_4_281_1","unstructured":"NCT02355028. [date unknown]. LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02355028"},{"key":"e_1_3_4_282_1","unstructured":"NCT02418754. 2015. Study of intravitreal REGN2176-3 in patients with neovascular (\u2018wet\u2019) age-related macular degeneration (AMD). ClinicalTrials.gov."},{"key":"e_1_3_4_283_1","unstructured":"NCT02434328. [date unknown]. Efficacy and safety of RTH258 versus aflibercept - study 2 (HARRIER). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02434328"},{"key":"e_1_3_4_284_1","unstructured":"NCT02462486. [date unknown]. Safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02462486"},{"key":"e_1_3_4_285_1","unstructured":"NCT02507388. [date unknown]. Safety and pharmacokinetics of RTH258 in subjects with age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02507388"},{"key":"e_1_3_4_286_1","unstructured":"NCT02515942. [date unknown]. CLG561 proof-of-concept study as a monotherapy and in combination with LFG316 in subjects with geographic atrophy (GA). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02515942"},{"key":"e_1_3_4_287_1","unstructured":"NCT02543229. [date unknown]. Study evaluating the safety pharmacokinetics and pharmacodynamics of OPT-302 with or without LucentisTM in patients with wet AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02543229"},{"key":"e_1_3_4_288_1","unstructured":"NCT02686658. [date unknown]. Zimura in participants with geographic atrophy secondary to dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02686658"},{"key":"e_1_3_4_289_1","unstructured":"NCT02713204. [date unknown]. Anti-angiOpoeitin 2 plus anti-vascular endothelial growth factor as a therapy for neovascular age related macular degeneration: evaluation of a fixed combination intravitreal injection. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02713204"},{"key":"e_1_3_4_290_1","unstructured":"NCT02859766. [date unknown]. Safety and pharmacokinetics of abicipar pegol intravitreal injections in patients with neovascular AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02859766"},{"key":"e_1_3_4_291_1","unstructured":"NCT03144999. [date unknown]. Treatment of advanced dry age related macular degeneration with AAVCAGsCD59. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03144999"},{"key":"e_1_3_4_292_1","unstructured":"NCT03345082. [date unknown]. A dose ranging study of OPT-302 with ranibizumab in neovascular (wet) AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03345082"},{"key":"e_1_3_4_293_1","unstructured":"NCT03386474. [date unknown]. Study of safety and efficacy of brolucizumab 6\u2009mg drug product intended for commercialization in patients with nAMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03386474"},{"key":"e_1_3_4_294_1","unstructured":"NCT03446144. [date unknown]. Safety and efficacy of IONIS-FB-LRX in up to 120 patients 55 and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). ClinicalTrials.gov. https:\/\/www.retinalphysician.com\/issues\/2018\/june-2018\/clinical-trial-update"},{"key":"e_1_3_4_295_1","unstructured":"NCT03479372. [date unknown]. Study of PAN-90806 eye drops suspension for neovascular AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03479372"},{"key":"e_1_3_4_296_1","unstructured":"NCT03525600. [date unknown]. Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03525600"},{"key":"e_1_3_4_297_1","unstructured":"NCT03626636. [date unknown]. A clinical trial designed to evaluate the safety and exploratory efficacy of 1.0\u2009Mg Luminate\u00ae (Alg-1001) as a treatment for non-exudative macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03626636"},{"key":"e_1_3_4_298_1","unstructured":"NCT03772665. [date unknown]. Safety and efficacy of emixustat in Stargardt disease (SeaSTAR). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03772665"},{"key":"e_1_3_4_299_1","unstructured":"NCT03777332. [date unknown]. Study to evaluate the safety of intravitreal APL-2 in patients diagnosed with geographic atrophy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03777332"},{"key":"e_1_3_4_300_1","unstructured":"NCT03815825. [date unknown]. A study to assess safety and efficacy of multiple doses of IONIS-FB-LRx in participants with geographic atrophy secondary to age-related macular degeneration (AMD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03815825"},{"key":"e_1_3_4_301_1","unstructured":"NCT03823287. [date unknown]. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (TENAYA). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03823287"},{"key":"e_1_3_4_302_1","unstructured":"NCT03823300. [date unknown]. A study to evaluate the efficacy and safety of faricimab in participants with neovascular age-related macular degeneration (LUCERNE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03823300"},{"key":"e_1_3_4_303_1","unstructured":"NCT03845582. [date unknown]. Phase 3 study of ALK-001 in geographic atrophy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03845582"},{"key":"e_1_3_4_304_1","unstructured":"NCT03846193. [date unknown]. FOCUS: a phase I\/II first in human study to evaluate the safety and efficacy of GT005 administered in subjects with dry AMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03846193"},{"key":"e_1_3_4_305_1","unstructured":"NCT04435366. [date unknown]. A phase 3 safety and efficacy study of intravitreal administration of zimura (complement C5 inhibitor). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04435366"},{"key":"e_1_3_4_306_1","unstructured":"NCT04514653. [date unknown]. RGX-314 gene therapy administered in the suprachoroidal space for participants with neovascular age-related macular degeneration (nAMD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04514653"},{"key":"e_1_3_4_307_1","unstructured":"NCT04566445. [date unknown]. HORIZON: a phase II study to evaluate the safety and efficacy of two doses of GT005. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04566445"},{"key":"e_1_3_4_308_1","unstructured":"NCT04643886. [date unknown]. A multiple dose study of repeat intravitreal injections of GEM103 in dry age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04643886"},{"key":"e_1_3_4_309_1","unstructured":"NCT04704921. [date unknown]. Pivotal 1 study of RGX-314 gene therapy in participants with nAMD. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04704921"},{"key":"e_1_3_4_310_1","unstructured":"NCT04989699. [date unknown]. Study evaluating the treatment of OTX-TKI for subjects with neovascular age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04989699"},{"key":"e_1_3_4_311_1","unstructured":"NCT05019521. [date unknown]. A study of danicopan in participants with geographic atrophy secondary to age-related macular degeneration. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05019521"},{"key":"e_1_3_4_312_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.04.030"},{"key":"e_1_3_4_313_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.043"},{"key":"e_1_3_4_314_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078005527.x"},{"issue":"7","key":"e_1_3_4_315_1","first-page":"1504","article-title":"Preliminary results from a first-in-human phase I\/II gene therapy study (FOCUS) of subretinally delivered GT005, an investigational AAV2 vector, in patients with geographic atrophy secondary to age-related macular degeneration","volume":"63","author":"Nielsen J","year":"2022","unstructured":"Nielsen J, et\u00a0al. 2022. Preliminary results from a first-in-human phase I\/II gene therapy study (FOCUS) of subretinally delivered GT005, an investigational AAV2 vector, in patients with geographic atrophy secondary to age-related macular degeneration. Investigative Ophthalmology & Visual Science. 63(7):1504.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_3_4_316_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1982.01030030920003"},{"key":"e_1_3_4_317_1","unstructured":"Novartis Pharma GmbH. [date unknown]. Study assessing the efficacy and safety of two different brolucizumab dosing regimens in patients with neovascular agerelated macular degeneration. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-004767-53-DE"},{"issue":"3","key":"e_1_3_4_318_1","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy","volume":"58","author":"Nowak JZ.","year":"2006","unstructured":"Nowak JZ. 2006. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 58(3):353\u2013363.","journal-title":"Pharmacol Rep"},{"key":"e_1_3_4_319_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574888X15666191218094020"},{"key":"e_1_3_4_320_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.9.1192"},{"key":"e_1_3_4_321_1","first-page":"1","article-title":"The effects of amniotic membrane on retinal pigment epithelial cell differentiation","volume":"11","author":"Ohno-Matsui K","year":"2005","unstructured":"Ohno-Matsui K, et\u00a0al. 2005. The effects of amniotic membrane on retinal pigment epithelial cell differentiation. Mol Vis. 11:1\u201310.","journal-title":"Mol Vis"},{"key":"e_1_3_4_322_1","first-page":"1022","article-title":"In vitro and in\u00a0vivo characterization of iris pigment epithelial cells cultured on amniotic membranes","volume":"12","author":"Ohno-Matsui K","year":"2006","unstructured":"Ohno-Matsui K, et\u00a0al. 2006. In vitro and in\u00a0vivo characterization of iris pigment epithelial cells cultured on amniotic membranes. Mol Vis. 12:1022\u20131032.","journal-title":"Mol Vis"},{"key":"e_1_3_4_323_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2016.10.002"},{"key":"e_1_3_4_324_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02497-w"},{"key":"e_1_3_4_325_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.10.008"},{"key":"e_1_3_4_326_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(90)32619-2"},{"issue":"5","key":"e_1_3_4_327_1","first-page":"363","article-title":"[Drusen in Bruch\u2019s membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration]","volume":"89","author":"Pauleikhoff D.","year":"1992","unstructured":"Pauleikhoff D. 1992. [Drusen in Bruch\u2019s membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration]. Ophthalmologe. 89(5):363\u2013386.","journal-title":"Ophthalmologe"},{"key":"e_1_3_4_328_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.01878.x"},{"key":"e_1_3_4_329_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11502"},{"key":"e_1_3_4_330_1","unstructured":"Pennington BO Clegg DO Melkoumian ZK Hikita ST. 2023. Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel synthetic substrate protocols and manufacturing for cell-based therapies defined culture of human embryonic stem cells and xeno-free D. 1\u201313."},{"key":"e_1_3_4_331_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85631-6"},{"key":"e_1_3_4_332_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0063-5"},{"key":"e_1_3_4_333_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15877"},{"key":"e_1_3_4_334_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21060"},{"issue":"7","key":"e_1_3_4_335_1","first-page":"469-A0006-469-A","article-title":"Nicotinamide and its role in reducing complement activation and oxidative stress in age-related macular degeneration","volume":"63","author":"Ploessl K","year":"2022","unstructured":"Ploessl K, Eifler A, Ramadani A, Schaetzler F, Weber BHF. 2022. Nicotinamide and its role in reducing complement activation and oxidative stress in age-related macular degeneration. Invest Ophthalmol Visual Sci. 63(7):469-A0006-469-A0006.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_336_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15067"},{"key":"e_1_3_4_337_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.02.019"},{"issue":"4","key":"e_1_3_4_338_1","first-page":"288","article-title":"[Laser treatment of circulatory disorders of the fundus oculi]","volume":"44","author":"Pournaras CJ","year":"1987","unstructured":"Pournaras CJ, Roth A. 1987. [Laser treatment of circulatory disorders of the fundus oculi]. Ther Umsch. 44(4):288\u2013301.","journal-title":"Ther Umsch"},{"key":"e_1_3_4_339_1","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.25.2.79.10158"},{"key":"e_1_3_4_340_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)74277-1"},{"key":"e_1_3_4_341_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12177-008-9005-3"},{"key":"e_1_3_4_342_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108765"},{"key":"e_1_3_4_343_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.04.009"},{"key":"e_1_3_4_344_1","doi-asserted-by":"publisher","DOI":"10.3390\/app11052154"},{"issue":"13","key":"e_1_3_4_345_1","first-page":"1309","article-title":"One year follow-up report on the rAAV.sFlt-1 phase I gene therapy trial for exudative age-related macular degeneration","volume":"55","author":"Rakoczy EP","year":"2014","unstructured":"Rakoczy EP, et\u00a0al. 2014. One year follow-up report on the rAAV.sFlt-1 phase I gene therapy trial for exudative age-related macular degeneration. Invest Ophthalmol Visual Sci. 55(13):1309.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"13","key":"e_1_3_4_346_1","first-page":"913","article-title":"A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration","volume":"51","author":"Ralston PG","year":"2010","unstructured":"Ralston PG Jr, Sloan D, Waters-Honcu D, Saigal S, Torkildsen G. 2010. A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Invest Ophthalmol Visual Sci. 51(13):913\u2013920.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_347_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000713"},{"key":"e_1_3_4_348_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082273"},{"issue":"6","key":"e_1_3_4_349_1","first-page":"1223","article-title":"Biodegradable polymer film as a source for formation of human fetal retinal pigment epithelium spheroids","volume":"40","author":"Rezai KA","year":"1999","unstructured":"Rezai KA, et\u00a0al. 1999. Biodegradable polymer film as a source for formation of human fetal retinal pigment epithelium spheroids. Invest Ophthalmol Vis Sci. 40(6):1223\u20131228.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_350_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00947084"},{"issue":"12","key":"e_1_3_4_351_1","first-page":"2662","article-title":"The immunogenic potential of human fetal retinal pigment epithelium and its relation to transplantation","volume":"38","author":"Rezai KA","year":"1997","unstructured":"Rezai KA, Semnani RT, Patel SC, Ernest JT, van Seventer GA. 1997. The immunogenic potential of human fetal retinal pigment epithelium and its relation to transplantation. Invest Ophthalmol Vis Sci. 38(12):2662\u20132671.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_352_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1529-1839(04)70049-4"},{"key":"e_1_3_4_353_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.optm.2011.08.008"},{"issue":"8","key":"e_1_3_4_354_1","first-page":"3388","article-title":"Delivery of CR2-fH using AAV vector therapy as a treatment strategy in mouse model of choroidal neovascularization","volume":"58","author":"Rohrer B","year":"2017","unstructured":"Rohrer B, et\u00a0al. 2017. Delivery of CR2-fH using AAV vector therapy as a treatment strategy in mouse model of choroidal neovascularization. Invest Ophthalmol Visual Sci. 58(8):3388.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_355_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.08.015"},{"key":"e_1_3_4_356_1","doi-asserted-by":"publisher","DOI":"10.1002\/term.1458"},{"key":"e_1_3_4_357_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1466"},{"key":"e_1_3_4_358_1","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2015.1115253"},{"key":"e_1_3_4_359_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2016.12.015"},{"issue":"3","key":"e_1_3_4_360_1","first-page":"414","article-title":"Softening of drusen and subretinal neovascularization","volume":"100","author":"Sarks SH","year":"1980","unstructured":"Sarks SH, Van Driel D, Maxwell L, Killingsworth M. 1980. Softening of drusen and subretinal neovascularization. Trans Ophthalmol Soc U K (1962). 100(3):414\u2013422.","journal-title":"Trans Ophthalmol Soc U K (1962)"},{"key":"e_1_3_4_361_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60028-2"},{"key":"e_1_3_4_362_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18681"},{"key":"e_1_3_4_363_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.7.995"},{"key":"e_1_3_4_364_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15841"},{"key":"e_1_3_4_365_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.02.040"},{"key":"e_1_3_4_366_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835"},{"key":"e_1_3_4_367_1","doi-asserted-by":"publisher","DOI":"10.1006\/exer.1993.1183"},{"key":"e_1_3_4_368_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202314095"},{"key":"e_1_3_4_369_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.04.014"},{"key":"e_1_3_4_370_1","unstructured":"Siddiqui F Aziz AA Khanani AM. 2020. Gene therapy for neovascular AMD. Retinal Physician. https:\/\/retinalphysician.com\/issues\/2020\/special-edition\/gene-therapy-for-neovascular-amd\/"},{"key":"e_1_3_4_371_1","first-page":"61","article-title":"Steroid implant alone and as an adjunct to anti-VEGF for CNV in AMD","author":"Singer MA.","year":"2012","unstructured":"Singer MA. 2012. Steroid implant alone and as an adjunct to anti-VEGF for CNV in AMD. Retina Today. 61\u201363. http:\/\/on.fb.me\/szUZRp","journal-title":"Retina Today"},{"key":"e_1_3_4_372_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-24426"},{"key":"e_1_3_4_373_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(01)00171-5"},{"key":"e_1_3_4_374_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.16174"},{"key":"e_1_3_4_375_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181f9c242"},{"key":"e_1_3_4_376_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4"},{"key":"e_1_3_4_377_1","doi-asserted-by":"publisher","DOI":"10.1002\/term.2221"},{"key":"e_1_3_4_378_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.02.005"},{"key":"e_1_3_4_379_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"},{"key":"e_1_3_4_380_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6989(03)00475-9"},{"key":"e_1_3_4_381_1","unstructured":"Stanford Medicine NCT04566445. [date unknown]. A phase II study to evaluate the safety and efficacy of two doses of GT005. ClinicalTrials.gov. https:\/\/clinicaltrials.stanford.edu\/trials\/h\/NCT04566445.html"},{"key":"e_1_3_4_382_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420"},{"key":"e_1_3_4_383_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.06.032"},{"key":"e_1_3_4_384_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2013.11.005"},{"key":"e_1_3_4_385_1","doi-asserted-by":"publisher","DOI":"10.1159\/000046474"},{"key":"e_1_3_4_386_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6112"},{"key":"e_1_3_4_387_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5386"},{"key":"e_1_3_4_388_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358531"},{"key":"e_1_3_4_389_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep25509"},{"key":"e_1_3_4_390_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00854"},{"key":"e_1_3_4_391_1","doi-asserted-by":"publisher","DOI":"10.7326\/ACPJC-2005-143-1-018"},{"key":"e_1_3_4_392_1","first-page":"2310","article-title":"Bruch\u2019s membrane aging decreases phagocytosis of outer segments by retinal pigment epithelium","volume":"13","author":"Sun K","year":"2007","unstructured":"Sun K, et\u00a0al. 2007. Bruch\u2019s membrane aging decreases phagocytosis of outer segments by retinal pigment epithelium. Mol Vis. 13:2310\u20132319.","journal-title":"Mol Vis"},{"key":"e_1_3_4_393_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97653"},{"key":"e_1_3_4_394_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02134-x"},{"key":"e_1_3_4_395_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2017.09.032"},{"key":"e_1_3_4_396_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503121231199655"},{"issue":"12","key":"e_1_3_4_397_1","first-page":"982","article-title":"[Retinal pigment epithelial cell transplantation: perspective]","volume":"100","author":"Tamai M.","year":"1996","unstructured":"Tamai M. 1996. [Retinal pigment epithelial cell transplantation: perspective]. Nippon Ganka Gakkai Zasshi. 100(12):982\u20131006.","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"e_1_3_4_398_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7TB00376E"},{"key":"e_1_3_4_399_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.49890"},{"key":"e_1_3_4_400_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1183-y"},{"issue":"7","key":"e_1_3_4_401_1","first-page":"465-A0002-465-A","article-title":"Role of warburg effect in age-related macular degeneration","volume":"63","author":"Tawfik AM","year":"2022","unstructured":"Tawfik AM, Samra YA, Rajpurohit P, Elkalawozgy W, Zaidi Y. 2022. Role of warburg effect in age-related macular degeneration. Invest Ophthalmol Visual Sci. 63(7):465-A0002-465-A0002.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"1","key":"e_1_3_4_402_1","first-page":"1","article-title":"Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization","volume":"64","author":"Terasaki H.","year":"2001","unstructured":"Terasaki H. 2001. Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization. Nagoya J Med Sci. 64(1-2):1\u20139.","journal-title":"Nagoya J Med Sci"},{"key":"e_1_3_4_403_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0193"},{"key":"e_1_3_4_404_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01007836"},{"issue":"2","key":"e_1_3_4_405_1","first-page":"467","article-title":"Fate of human retinal pigment epithelial cells seeded onto layers of human Bruch\u2019s membrane","volume":"40","author":"Tezel TH","year":"1999","unstructured":"Tezel TH, Kaplan HJ, Del Priore LV. 1999. Fate of human retinal pigment epithelial cells seeded onto layers of human Bruch\u2019s membrane. Invest Ophthalmol Vis Sci. 40(2):467\u2013476.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_406_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19238"},{"key":"e_1_3_4_407_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.166728"},{"key":"e_1_3_4_408_1","doi-asserted-by":"publisher","DOI":"10.1016\/0142-9612(96)85570-0"},{"key":"e_1_3_4_409_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.10.1350"},{"key":"e_1_3_4_410_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2008.09.039"},{"key":"e_1_3_4_411_1","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.16.12.1236.5031"},{"key":"e_1_3_4_412_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.11.010"},{"issue":"9","key":"e_1_3_4_413_1","first-page":"471","article-title":"[Photodynamic therapy for choroidal neovascularization not caused by age related macular degeneration or pathologic myopia]","volume":"78","author":"Torr\u00f3n Fern\u00e1ndez-Blanco C","year":"2003","unstructured":"Torr\u00f3n Fern\u00e1ndez-Blanco C, et\u00a0al. 2003. [Photodynamic therapy for choroidal neovascularization not caused by age related macular degeneration or pathologic myopia]. Arch Soc Esp Oftalmol. 78(9):471\u2013476.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"e_1_3_4_414_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2022.104038"},{"key":"e_1_3_4_415_1","doi-asserted-by":"publisher","DOI":"10.1111\/dgd.12704"},{"key":"e_1_3_4_416_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.88.1.110"},{"key":"e_1_3_4_417_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.06.007"},{"key":"e_1_3_4_418_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0084-392X(08)70302-2"},{"key":"e_1_3_4_419_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.01.023"},{"key":"e_1_3_4_420_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/895147"},{"key":"e_1_3_4_421_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100140393005"},{"issue":"8","key":"e_1_3_4_422_1","first-page":"13","article-title":"Effect of sildenafil citrate on choroidal thickness in age-related macular degeneration","volume":"58","author":"Vuong VS","year":"2017","unstructured":"Vuong VS, et\u00a0al. 2017. Effect of sildenafil citrate on choroidal thickness in age-related macular degeneration. Invest Ophthalmol Visual Sci. 58(8):13.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_423_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010329"},{"key":"e_1_3_4_424_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052360"},{"key":"e_1_3_4_425_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2013.07.029"},{"key":"e_1_3_4_426_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2017.12.009"},{"key":"e_1_3_4_427_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0739-x"},{"key":"e_1_3_4_428_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-199911000-00011"},{"key":"e_1_3_4_429_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013257.pub2"},{"key":"e_1_3_4_430_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci.2017.10.01"},{"key":"e_1_3_4_431_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040702"},{"key":"e_1_3_4_432_1","doi-asserted-by":"publisher","DOI":"10.1177\/2041731417720841"},{"key":"e_1_3_4_433_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2007.10.056"},{"key":"e_1_3_4_434_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10856-005-4710-y"},{"key":"e_1_3_4_435_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.30953"},{"key":"e_1_3_4_436_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.008"},{"key":"e_1_3_4_437_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_438_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018282"},{"key":"e_1_3_4_439_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.08.040"},{"key":"e_1_3_4_440_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/623509"},{"key":"e_1_3_4_441_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2008.10.045"},{"issue":"2","key":"e_1_3_4_442_1","first-page":"142","article-title":"Vitreoretinal surgical technique for transplanting retinal pigment epithelium in rabbit retina","volume":"36","author":"Yamaguchi K","year":"1992","unstructured":"Yamaguchi K, et\u00a0al. 1992. Vitreoretinal surgical technique for transplanting retinal pigment epithelium in rabbit retina. Jpn J Ophthalmol. 36(2):142\u2013150.","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_3_4_443_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-018-3021-3"},{"key":"e_1_3_4_444_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.3082"},{"key":"e_1_3_4_445_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.19-26690"},{"key":"e_1_3_4_446_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02126-5"},{"key":"e_1_3_4_447_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604255103"},{"key":"e_1_3_4_448_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01608-8"},{"key":"e_1_3_4_449_1","doi-asserted-by":"publisher","DOI":"10.3980\/j.issn.2222-3959.2010.02.01"},{"key":"e_1_3_4_450_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1027763"},{"key":"e_1_3_4_451_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13502"},{"key":"e_1_3_4_452_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.425"},{"key":"e_1_3_4_453_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.19"}],"container-title":["Pharmaceutical Development and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10837450.2025.2562196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:46:18Z","timestamp":1762361178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10837450.2025.2562196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":452,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9,14]]}},"alternative-id":["10.1080\/10837450.2025.2562196"],"URL":"https:\/\/doi.org\/10.1080\/10837450.2025.2562196","relation":{},"ISSN":["1083-7450","1097-9867"],"issn-type":[{"value":"1083-7450","type":"print"},{"value":"1097-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}